Please assess the completion status of the following clinical trial:

Trial Title: Metformin for the Prevention of Oral Cancer in Patients With Oral Premalignant Lesions

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-85~* Clinical appearance of lesion~  * Homogenous leukoplakia~ * Non- homogenous leukoplakia~ * Erythroplakia~ * Proliferative verrucous leukoplakia~* Histologic appearance~  * No dysplasia~ * Mild dysplasia~ * Moderate dysplasia~ * Severe dysplasia~* Diabetics: if on metformin, will get them to 2000 mg per day, if not, will add metformin in consultation with endocrinologist~* All subjects must be able to comprehend and sign a written informed consent document~* Willing and able to be available for the duration of the study~* In general good health with no contraindication to biopsy or metformin therapy~* Laboratory results~Exclusion Criteria:~* Carcinoma in-situ, verrucous carcinoma, invasive squamous cell carcinoma (SCCa)~* Exclude systemic causes of the lesion: pemphigus, pemphigoid, systemic lupus erythematosus (SLE), lichenoid drug reaction, human immunodeficiency virus (HIV), syphilis~* Exclude local inciting factors: rule out (r/o) but allowing 2 weeks to pass and see if there is resolution, if not and doesn't resolve with local measures, medical treatment, enroll~  * Frictional: sharp tooth~ * Trauma~* Immunosuppression by natural illness or medically induced~* Hypersensitivity or allergic reaction to metformin or some other contraindication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Prevention (metformin) (Type: EXPERIMENTAL): Patients receive metformin PO QD on days 1-3 and then PO BID for up to 12 months in the absence of unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).